Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma Cardiovasc Intervent Radiol https://doi.org/10.1007/s00270-018-1993-1 CASE REP O RT Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma 1 2 3 2 • • • • Eric Wehrenberg-Klee Lipika Goyal Matthew Dugan Andrew X. Zhu Suvranu Ganguli Received: 4 May 2018 / Accepted: 19 May 2018 Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2018 Abstract Nivolumab has recently received approval by the Introduction Food and Drug Administration for treatment of advanced hepatocellular carcinoma (HCC) in patients previously Nivolumab has recently received conditional FDA treated with sorafenib. Nivolumabs’ overall response rate approval for patients with advanced HCC previously trea- of 20% (El-Khoueiry et al. in Lancet 389:2492–2502, ted with sorafenib, but demonstrates a modest response rate 2017) is a step forward for these patients, but there is of 20%. Further trials are ongoing with nivolumab as well significant room for improvement. We describe a case of as other checkpoint inhibitors, with the anticipation that combining Y-90 radioembolization with nivolumab for checkpoint blockade will be an effective strategy in HCC. treatment of angioinvasive HCC, which successfully Due to the modest overall response rate to programmed bridged patient to partial http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png CardioVascular and Interventional Radiology Springer Journals

Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

Loading next page...
 
/lp/springer_journal/y-90-radioembolization-combined-with-a-pd-1-inhibitor-for-advanced-degWRHLr4r
Publisher
Springer US
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Subject
Medicine & Public Health; Imaging / Radiology; Cardiology; Nuclear Medicine; Ultrasound
ISSN
0174-1551
eISSN
1432-086X
D.O.I.
10.1007/s00270-018-1993-1
Publisher site
See Article on Publisher Site

Abstract

Cardiovasc Intervent Radiol https://doi.org/10.1007/s00270-018-1993-1 CASE REP O RT Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma 1 2 3 2 • • • • Eric Wehrenberg-Klee Lipika Goyal Matthew Dugan Andrew X. Zhu Suvranu Ganguli Received: 4 May 2018 / Accepted: 19 May 2018 Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2018 Abstract Nivolumab has recently received approval by the Introduction Food and Drug Administration for treatment of advanced hepatocellular carcinoma (HCC) in patients previously Nivolumab has recently received conditional FDA treated with sorafenib. Nivolumabs’ overall response rate approval for patients with advanced HCC previously trea- of 20% (El-Khoueiry et al. in Lancet 389:2492–2502, ted with sorafenib, but demonstrates a modest response rate 2017) is a step forward for these patients, but there is of 20%. Further trials are ongoing with nivolumab as well significant room for improvement. We describe a case of as other checkpoint inhibitors, with the anticipation that combining Y-90 radioembolization with nivolumab for checkpoint blockade will be an effective strategy in HCC. treatment of angioinvasive HCC, which successfully Due to the modest overall response rate to programmed bridged patient to partial

Journal

CardioVascular and Interventional RadiologySpringer Journals

Published: May 29, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off